- $40.87m
- $19.20m
- $17.32m
- 63
- 41
- 79
- 64
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 1.22 | ||
Price to Tang. Book | 1.64 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 2.36 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -22.18% | ||
Return on Equity | -20.52% | ||
Operating Margin | -44.4% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 31.34 | 29.7 | 33.64 | 19.8 | 17.32 | 18.51 | 23.51 | -7.53% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
iCAD, Inc. is a global medical technology company, which provides cancer detection and therapy solutions. The Company is focused on providing breast cancer detection solutions built on artificial intelligence (AI) that empowers radiologists to find cancers. Its solutions include advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the most prevalent cancers earlier, and a range of high-performance, AI and computer-aided detection (CAD) systems and workflow solutions for 2D and 3D mammography, magnetic resonance imaging and computed tomography (CT). The Company’s Breast AI Suite offers a triple threat of clinically proven cancer detection, density assessment, and risk evaluation solutions, designed to accelerate discovery and improve outcomes. It also offers ProFound AI, a digital breast tomosynthesis (DBT) cancer detection and workflow solution.
Directors
- Michael Klein CHM (67)
- Stacey Stevens PRE (53)
- Charles Carter CFO (54)
- Jonathan Go CTO (54)
- Nathaniel Dalton LED (54)
- Dana Brown IND (50)
- Timothy Irish IND (58)
- Rakesh Patel IND (48)
- Andrew Sassine IND (56)
- Susan Wood IND (58)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 24th, 1984
- Public Since
- December 13th, 1984
- No. of Shareholders
- 80
- No. of Employees
- 67
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 26,540,030
- Address
- 98 Spit Brook Rd Ste 100, NASHUA, 03062-5737
- Web
- https://www.icadmed.com/
- Phone
- +1 6038825200
- Auditors
- BDO USA, LLP
Upcoming Events for ICAD
Q2 2024 ICAD Inc Earnings Release
Similar to ICAD
Accelerate Diagnostics
NASDAQ Capital Market
Acutus Medical
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
FAQ
As of Today at 19:11 UTC, shares in icad are trading at $1.54. This share price information is delayed by 15 minutes.
Shares in icad last closed at $1.54 and the price had moved by +6.21% over the past 365 days. In terms of relative price strength the icad share price has underperformed the S&P500 Index by -11.62% over the past year.
The overall consensus recommendation for icad is Buy. You can view the full broker recommendation list by unlocking its StockReport.
icad does not currently pay a dividend.
icad does not currently pay a dividend.
icad does not currently pay a dividend.
To buy shares in icad you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.54, shares in icad had a market capitalisation of $40.87m.
Here are the trading details for icad:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ICAD
Based on an overall assessment of its quality, value and momentum icad is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in icad is $4.83. That is 213.64% above the last closing price of $1.54.
Analysts covering icad currently have a consensus Earnings Per Share (EPS) forecast of -$0.23 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like icad. Over the past six months, its share price has underperformed the S&P500 Index by -18.29%.
As of the last closing price of $1.54, shares in icad were trading -16.19% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The icad PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.54.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
icad's management team is headed by:
- Michael Klein - CHM
- Stacey Stevens - PRE
- Charles Carter - CFO
- Jonathan Go - CTO
- Nathaniel Dalton - LED
- Dana Brown - IND
- Timothy Irish - IND
- Rakesh Patel - IND
- Andrew Sassine - IND
- Susan Wood - IND